Build
We start software products in-house for health, peptides, and GLP-1.
Each product gets a fixed build window and one success test. If operators use it we keep going; if they don't we shut it down and write up why.
Studio · Est. 2026
Software products for the health and supplement industry — peptide systems, GLP-1 trackers, and the operating tools those businesses actually run.
No obligation, and nothing is shared with anyone. We reply within 48 hours.
01Operating numbers
Most studios stop at the first release. We stay on after launch because peptide systems, GLP-1 trackers, and the rest of a health product are the operating work.
We start software products in-house for health, peptides, and GLP-1.
Each product gets a fixed build window and one success test. If operators use it we keep going; if they don't we shut it down and write up why.
We run the product after launch — tracking, support, billing, growth.
Shipping the first version is the start. The studio stays on peptide systems, GLP-1 trackers, and the rest of the stack that turns a release into a business.
We keep what we build. We are not a fund and there is no exit clock.
No investors means no timeline we have to sell against. A product stays in the studio as long as it serves its users and covers its costs.
The products currently in the studio — peptide software, GLP-1, and Height. All three are scaling.
| # | Product | Category | Status | Metric | Since |
|---|---|---|---|---|---|
| 01 | Peptide Software | Peptide systems | SCALING | Scaling | 2026 |
| 02 | GLP-1 | GLP-1 trackers | SCALING | Scaling | 2026 |
| 03 | Height | Health software | SCALING | Scaling | 2026 |
Peptide systems
GLP-1 trackers
Health software
If most of these are true, we want to hear from you. If you're unsure, send it anyway — we'd rather say no quickly than have you not ask.
Software clinics, supplement brands, and peptide operators can actually run — not a feature looking for a home.
If it takes more than two sentences to describe the job it does, it is the wrong product to start.
One job for one kind of operator. Peptide systems, GLP-1 trackers, supplement workflows — scope that can ship, then grow.
Software that can run without a sales floor. Low-touch beats high-touch for a small studio.
We start products below the size most funds bother with. There is no floor that disqualifies a focused health tool.
The people who build it stay on it. We do not hand a peptide or GLP-1 system off to a group that did not ship it.
What we bring to a product we own
Written out plainly, because you'd ask them on the call anyway.
Fair. We're a young studio and we don't ask you to take that on faith — we'll show you the health software we run, put you in touch with anyone we've built with, and say so where we don't have a track record yet.
It probably isn't. We deliberately start below the size funds and accelerators work in, because that's where focused peptide, GLP-1, and supplement software actually gets built instead of pitched.
No. We build products to operate them. The people who ship the software stay on it. Breaking that is how you lose the thing you just made.
We give you a yes or no within two weeks of a real conversation, and we tell you why either way. Work that stalls usually stalled because nobody intended to start.
No. We'd rather the people who build it keep running it, but a clean, short handover works if that's the deal. What you do next is your business.
Then talk. A good portion of what we do starts as a conversation with someone who wasn't founding anything yet, and we're not going to run a pipeline at you for it.
A company you're starting, a partnership, or just a conversation. We reply to everything within 48 hours.